These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 36377303)

  • 21. Comparison of vaccine-induced antibody neutralization against SARS-CoV-2 variants of concern following primary and booster doses of COVID-19 vaccines.
    Hvidt AK; Baerends EAM; Søgaard OS; Stærke NB; Raben D; Reekie J; Nielsen H; Johansen IS; Wiese L; Benfield TL; Iversen KK; Mustafa AB; Juhl MR; Petersen KT; Ostrowski SR; Lindvig SO; Rasmussen LD; Schleimann MH; Andersen SD; Juhl AK; Dietz LL; Andreasen SR; Lundgren J; Østergaard L; Tolstrup M;
    Front Med (Lausanne); 2022; 9():994160. PubMed ID: 36262278
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Diagnostic Sensitivity of Saliva and Other Respiratory Tract Samples of SARS-CoV-2 Variants in Patients with COVID-19.
    Lawrence Panchali MJ; Kim CM; Lee YM; Seo JW; Kim DY; Yun NR; Kim DM
    Microbiol Spectr; 2023 Mar; 11(2):e0307622. PubMed ID: 36976007
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effectiveness of mRNA COVID-19 vaccines against Omicron and Delta variants in a matched test-negative case-control study among US veterans.
    Young-Xu Y; Zwain GM; Izurieta HS; Korves C; Powell EI; Smith J; Balajee A; Holodniy M; Beenhouwer DO; Rodriguez-Barradas MC; Brown ST; Marconi VC
    BMJ Open; 2022 Aug; 12(8):e063935. PubMed ID: 35922100
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Effectiveness of a COVID-19 Additional Primary or Booster Vaccine Dose in Preventing SARS-CoV-2 Infection Among Nursing Home Residents During Widespread Circulation of the Omicron Variant - United States, February 14-March 27, 2022.
    Prasad N; Derado G; Nanduri SA; Reses HE; Dubendris H; Wong E; Soe MM; Li Q; Dollard P; Bagchi S; Edwards J; Shang N; Budnitz D; Bell J; Verani JR; Benin A; Link-Gelles R; Jernigan J; Pilishvili T
    MMWR Morb Mortal Wkly Rep; 2022 May; 71(18):633-637. PubMed ID: 35511708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Why Does the SARS-CoV-2 Delta VOC Spread So Rapidly? Universal Conditions for the Rapid Spread of Respiratory Viruses, Minimum Viral Loads for Viral Aerosol Generation, Effects of Vaccination on Viral Aerosol Generation, and Viral Aerosol Clouds.
    Lee BU
    Int J Environ Res Public Health; 2021 Sep; 18(18):. PubMed ID: 34574724
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Real-world effectiveness of homologous and heterologous BNT162b2, CoronaVac, and AZD1222 booster vaccination against Delta and Omicron SARS-CoV-2 infection.
    Suah JL; Tng BH; Tok PSK; Husin M; Thevananthan T; Peariasamy KM; Sivasampu S
    Emerg Microbes Infect; 2022 Dec; 11(1):1343-1345. PubMed ID: 35499301
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effectiveness of mRNA vaccine boosters against infection with the SARS-CoV-2 omicron (B.1.1.529) variant in Spain: a nationwide cohort study.
    Monge S; Rojas-Benedicto A; Olmedo C; Mazagatos C; José Sierra M; Limia A; Martín-Merino E; Larrauri A; Hernán MA;
    Lancet Infect Dis; 2022 Sep; 22(9):1313-1320. PubMed ID: 35658998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. SARS-CoV-2 Omicron Variant, Lineage BA.1, Is Associated with Lower Viral Load in Nasopharyngeal Samples Compared to Delta Variant.
    Sentis C; Billaud G; Bal A; Frobert E; Bouscambert M; Destras G; Josset L; Lina B; Morfin F; Gaymard A; The Covid-Diagnosis Hcl Study Group
    Viruses; 2022 Apr; 14(5):. PubMed ID: 35632661
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [COVID-19 infections and effectiveness of the vaccination among healthcare workers].
    Rojkovich B; Németh D; Dinya E; Nagy E; Török E; Lázár I; Perduk A; Géher P; Nagy G
    Orv Hetil; 2023 Feb; 164(5):163-171. PubMed ID: 36739547
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant - National Healthcare Safety Network, March 1-August 1, 2021.
    Nanduri S; Pilishvili T; Derado G; Soe MM; Dollard P; Wu H; Li Q; Bagchi S; Dubendris H; Link-Gelles R; Jernigan JA; Budnitz D; Bell J; Benin A; Shang N; Edwards JR; Verani JR; Schrag SJ
    MMWR Morb Mortal Wkly Rep; 2021 Aug; 70(34):1163-1166. PubMed ID: 34437519
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Immunogenicity of convalescent and vaccinated sera against clinical isolates of ancestral SARS-CoV-2, Beta, Delta, and Omicron variants.
    Banerjee A; Lew J; Kroeker A; Baid K; Aftanas P; Nirmalarajah K; Maguire F; Kozak R; McDonald R; Lang A; Gerdts V; Straus SE; Gilbert L; Li AX; Mozafarihashjin M; Walmsley S; Gingras AC; Wrana JL; Mazzulli T; Colwill K; McGeer AJ; Mubareka S; Falzarano D
    Med; 2022 Jun; 3(6):422-432.e3. PubMed ID: 35437520
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The British variant of the new coronavirus-19 (Sars-Cov-2) should not create a vaccine problem.
    Conti P; Caraffa A; Gallenga CE; Kritas SK; Frydas I; Younes A; Di Emidio P; Tetè G; Pregliasco F; Ronconi G
    J Biol Regul Homeost Agents; 2021; 35(1):1-4. PubMed ID: 33377359
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effectiveness of COVID-19 vaccines against SARS-CoV-2 variants of concern: a systematic review and meta-analysis.
    Zeng B; Gao L; Zhou Q; Yu K; Sun F
    BMC Med; 2022 May; 20(1):200. PubMed ID: 35606843
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A Glycosylated RBD Protein Induces Enhanced Neutralizing Antibodies against Omicron and Other Variants with Improved Protection against SARS-CoV-2 Infection.
    Shi J; Zheng J; Tai W; Verma AK; Zhang X; Geng Q; Wang G; Guan X; Malisheni MM; Odle AE; Zhang W; Li F; Perlman S; Du L
    J Virol; 2022 Sep; 96(17):e0011822. PubMed ID: 35972290
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Risk and symptoms of COVID-19 in health professionals according to baseline immune status and booster vaccination during the Delta and Omicron waves in Switzerland-A multicentre cohort study.
    Babouee Flury B; Güsewell S; Egger T; Leal O; Brucher A; Lemmenmeier E; Meier Kleeb D; Möller JC; Rieder P; Rütti M; Schmid HR; Stocker R; Vuichard-Gysin D; Wiggli B; Besold U; McGeer A; Risch L; Friedl A; Schlegel M; Kuster SP; Kahlert CR; Kohler P;
    PLoS Med; 2022 Nov; 19(11):e1004125. PubMed ID: 36342956
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effectiveness of the BNT162b2 (Pfizer-BioNTech) and the ChAdOx1 nCoV-19 (Oxford-AstraZeneca) vaccines for reducing susceptibility to infection with the Delta variant (B.1.617.2) of SARS-CoV-2.
    Pattni K; Hungerford D; Adams S; Buchan I; Cheyne CP; García-Fiñana M; Hall I; Hughes DM; Overton CE; Zhang X; Sharkey KJ
    BMC Infect Dis; 2022 Mar; 22(1):270. PubMed ID: 35307024
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Neutralization of Severe Acute Respiratory Syndrome Coronavirus 2 Omicron Variant by Sera From BNT162b2 or CoronaVac Vaccine Recipients.
    Lu L; Mok BWY; Chen LL; Chan JMC; Tsang OTY; Lam BHS; Chuang VWM; Chu AWH; Chan WM; Ip JD; Chan BPC; Zhang R; Yip CCY; Cheng VCC; Chan KH; Jin DY; Hung IFN; Yuen KY; Chen H; To KKW
    Clin Infect Dis; 2022 Aug; 75(1):e822-e826. PubMed ID: 34915551
    [TBL] [Abstract][Full Text] [Related]  

  • 38. RNA loads of severe acute respiratory syndrome coronavirus 2 in patients with breakthrough coronavirus disease 2019 caused by the Delta and Omicron variants.
    de Michelena P; Torres I; Ferrando EC; Olea B; González-Candelas F; Sánchez G; Navarro D
    Clin Microbiol Infect; 2023 Feb; 29(2):256.e1-256.e4. PubMed ID: 36115649
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Omicron and Delta Variants of SARS-CoV-2: A Systematic Review of Current Evidence.
    SeyedAlinaghi S; Afsahi AM; Mirzapour P; Afzalian A; Shahidi R; Dashti M; Ghasemzadeh A; Paranjkhoo P; Parsaei Z; Pashaei A; Mohammadi P; Najafi MS; Mahrokhi S; Matini P; Moradi A; Karimi A; Afroughi S; Mehraeen E; Dadras O
    Infect Disord Drug Targets; 2024; 24(7):e050324227686. PubMed ID: 38445691
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Immunogenicity, Effectiveness, and Safety of Inactivated Virus (CoronaVac) Vaccine in a Two-Dose Primary Protocol and BNT162b2 Heterologous Booster in Brazil (Immunita-001): A One Year Period Follow Up Phase 4 Study.
    Grenfell RFQ; Almeida NBF; Filgueiras PS; Corsini CA; Gomes SVC; de Miranda DAP; Lourenço AJ; Martins-Filho OA; de Oliveira JG; Teixeira-Carvalho A; Campos GRF; Nogueira ML; Alves PA; Fernandes GR; Castilho LR; Lima TM; de Abreu DPB; Alvim RGF; Silva TBS; Jeremias WJ; Otta DA; Campi-Azevedo AC;
    Front Immunol; 2022; 13():918896. PubMed ID: 35757764
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.